BMY vs. PG
BMY (Bristol-Myers Squibb Company) and PG (The Procter & Gamble Company) are both stocks. BMY operates in Drug Manufacturers - General (Healthcare), while PG operates in Household & Personal Products (Consumer Defensive). Over the past 10 years, BMY returned 1.11%/yr vs 8.69%/yr for PG. At a 0.36 correlation, their price movements are largely independent.
Performance
BMY vs. PG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BMY achieves a 10.98% return, which is significantly higher than PG's 5.11% return. Over the past 10 years, BMY has underperformed PG with an annualized return of 1.11%, while PG has yielded a comparatively higher 8.69% annualized return.
BMY
- 1D
- 1.81%
- 1M
- 2.41%
- YTD
- 10.98%
- 6M
- 10.63%
- 1Y
- 32.66%
- 3Y*
- 1.71%
- 5Y*
- 1.39%
- 10Y*
- 1.11%
PG
- 1D
- -0.38%
- 1M
- 3.41%
- YTD
- 5.11%
- 6M
- 4.19%
- 1Y
- -4.47%
- 3Y*
- 1.88%
- 5Y*
- 4.56%
- 10Y*
- 8.69%
BMY vs. PG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 10.98% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
PG The Procter & Gamble Company | 5.11% | -12.26% | 17.25% | -0.86% | -5.05% | 20.52% | 14.15% | 39.70% | 3.57% | 12.69% |
Correlation
The correlation between BMY and PG is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 1972 | 0.36 |
Fundamentals
BMY:
$119.67B
PG:
$358.73B
BMY:
$3.56
PG:
$5.24
BMY:
16.43
PG:
28.32
BMY:
0.94
PG:
6.93
BMY:
2.47
PG:
4.15
BMY:
5.96
PG:
6.65
BMY:
$48.48B
PG:
$86.72B
BMY:
$33.33B
PG:
$43.64B
BMY:
$13.34B
PG:
$22.63B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. PG — Risk / Return Rank
BMY
PG
BMY vs. PG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and The Procter & Gamble Company (PG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BMY | PG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.44 | ||
| Sortino ratioReturn per unit of downside risk | +2.08 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 0.98 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 2.62 | -0.29 | +2.91 |
| Martin ratioReturn relative to average drawdown | 5.83 | -0.52 | +6.35 |
Loading charts...
Drawdowns
BMY vs. PG - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, which is greater than PG's maximum drawdown of -54.25%. Use the drawdown chart below to compare losses from any high point for BMY and PG.
Loading charts...
Drawdown Indicators
| BMY | PG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -54.25% | -17.78% |
Max Drawdown (1Y)Largest decline over 1 year | -12.53% | -15.52% | +2.99% |
Max Drawdown (3Y)Largest decline over 3 years | -36.02% | -21.15% | -14.87% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -23.77% | -23.90% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -23.77% | -23.90% |
Current DrawdownCurrent decline from peak | -15.73% | -13.96% | -1.77% |
Average DrawdownAverage peak-to-trough decline | -22.37% | -12.16% | -10.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.62% | 8.57% | -2.95% |
Volatility
BMY vs. PG - Volatility Comparison
Bristol-Myers Squibb Company (BMY) has a higher volatility of 9.25% compared to The Procter & Gamble Company (PG) at 7.27%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than PG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BMY | PG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.25% | 7.27% | +1.98% |
Volatility (6M)Calculated over the trailing 6-month period | 18.43% | 15.16% | +3.27% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.33% | 19.04% | +8.29% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.15% | 17.89% | +6.26% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.32% | 19.07% | +6.25% |
Dividends
BMY vs. PG - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 4.27%, more than PG's 2.87% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.27% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
PG The Procter & Gamble Company | 2.87% | 2.91% | 2.36% | 2.55% | 2.38% | 2.08% | 2.24% | 2.37% | 3.09% | 2.98% | 3.18% | 3.31% |
Financials
BMY vs. PG - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and The Procter & Gamble Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. PG - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
PG - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Procter & Gamble Company reported a gross profit of 10.51B and revenue of 21.24B. Therefore, the gross margin over that period was 49.5%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
PG - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Procter & Gamble Company reported an operating income of 4.58B and revenue of 21.24B, resulting in an operating margin of 21.6%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
PG - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Procter & Gamble Company reported a net income of 18.50M and revenue of 21.24B, resulting in a net margin of 0.1%.
Frequently Asked Questions
BMY and PG have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (9.25%) compared to PG (7.27%). In terms of maximum drawdown, BMY dropped -72.03% vs PG's -54.25%.
BMY currently has the higher Sharpe Ratio (1.20 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BMY and PG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer